Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) on Behalf of Progenics Shareholders and Encourages Progenics Investors to Contact the Firm
NEW YORK, Oct. 2, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) on behalf of Progenics shareholders concerning the proposed merger with Lantheus Holdings, Inc.
Pursuant to the proposed transaction announced on October 2, 2019, Progenics shareholders will receive 0.2502 shares of Lantheus common stock for each share of Progenics common stock owned. The investigation focuses on whether Progenics and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company's shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
If you own Progenics shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by email at [email protected], or by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation of Progenics please go to https://bespc.com/pgnx/. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.